Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies.

MLA

Caputo, Jean, et al. “Combination Ruxolitinib and Belumosudil Is Tolerable and Induces Responses despite Treatment Failure as Monotherapies.” Leukemia & Lymphoma, Oct. 2024, pp. 1–8. EBSCOhost, https://doi.org/10.1080/10428194.2024.2409876.

APA

Caputo, J., Peddireddi, A., Bhatta, S., Huang, Y., Bezerra, E., Brammer, J., Larkin, K., Mims, A., Vasu, S., Wall, S., & Choe, H. (2024). Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies. Leukemia & Lymphoma, 1–8. https://doi.org/10.1080/10428194.2024.2409876

Chicago

Caputo, Jean, Ayush Peddireddi, Subodh Bhatta, Ying Huang, Evandro Bezerra, Jonathan Brammer, Karilyn Larkin, et al. 2024. “Combination Ruxolitinib and Belumosudil Is Tolerable and Induces Responses despite Treatment Failure as Monotherapies.” Leukemia & Lymphoma, October, 1–8. doi:10.1080/10428194.2024.2409876.